Keywords: Canada, Trade deal with EU, Rx&D, NUPGE, CGPA, Intellectual property

Canada-EU Trade deal proposals could add C$2.8 billion to Canada’s drug costs; report slammed by Rx&D

Article | 09 February 2011

According to a study from the Canadian Generic Pharmaceutical Association (CGPA), changes to Canada’s drug patent system proposed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in